tetano
Editor, Senior Moderator
J Appl Microbiol
. 2023 Oct 10:lxad232.
doi: 10.1093/jambio/lxad232. Online ahead of print. Ruxolitinib accelerates Influenza A virus adaptation in the MDCK cell line
Hana Malenovská[SUP] 1 [/SUP]
Affiliations
Aim: To investigate the effect of ruxolitinib medium supplement, separately and in combination with trypsin, on Influenza A virus (IAV) adaptation and propagation in the MDCK cell line.
Methods and results: Two consecutive passages of three egg-based IAV virus strains were performed in the MDCK cell line with medium (a) without additives; (b) with a combination of ruxolitinib and trypsin; (c) with ruxolitinib and (d) trypsin. Adaptation without medium additive failed in both passages. After a single passage, the probability of IAV adaptation was highly significantly influenced by the type of additive (GLM-b, χ22=23.84, P<0.00001). The highest probability of adaptation was achieved with the combination of ruxolitinib and trypsin, followed by ruxolitinib alone and trypsin. After the two consecutive passages, the influence of the type of medium additive on the probability of virus adaptation was no longer significant. In two of three IAV MDCK-adapted strains, the type of medium additive had no significant influence on virus yields.
Conclusion: Ruxolitinib accelerates adaptation of IAV in the MDCK cell line both individually and together with trypsin.
Keywords: Influenza A virus; MDCK; adaptation; ruxolitinib; trypsin.
. 2023 Oct 10:lxad232.
doi: 10.1093/jambio/lxad232. Online ahead of print. Ruxolitinib accelerates Influenza A virus adaptation in the MDCK cell line
Hana Malenovská[SUP] 1 [/SUP]
Affiliations
- PMID: 37816667
- DOI: 10.1093/jambio/lxad232
Aim: To investigate the effect of ruxolitinib medium supplement, separately and in combination with trypsin, on Influenza A virus (IAV) adaptation and propagation in the MDCK cell line.
Methods and results: Two consecutive passages of three egg-based IAV virus strains were performed in the MDCK cell line with medium (a) without additives; (b) with a combination of ruxolitinib and trypsin; (c) with ruxolitinib and (d) trypsin. Adaptation without medium additive failed in both passages. After a single passage, the probability of IAV adaptation was highly significantly influenced by the type of additive (GLM-b, χ22=23.84, P<0.00001). The highest probability of adaptation was achieved with the combination of ruxolitinib and trypsin, followed by ruxolitinib alone and trypsin. After the two consecutive passages, the influence of the type of medium additive on the probability of virus adaptation was no longer significant. In two of three IAV MDCK-adapted strains, the type of medium additive had no significant influence on virus yields.
Conclusion: Ruxolitinib accelerates adaptation of IAV in the MDCK cell line both individually and together with trypsin.
Keywords: Influenza A virus; MDCK; adaptation; ruxolitinib; trypsin.